A clinical trial of a potential treatment for Ebola has started in Liberia, with the first Ebola patient receiving the study drug on 2 January.
The trial is led by the University of Oxford and is taking place at Médecins Sans Frontières (MSF)’s ELWA 3 Ebola Management Centre in Monrovia.
Funded by the Wellcome Trust, the trial aims to evaluate the effectiveness of an oral antiviral drug called brincidofovir in patients with Ebola virus disease. Brincidofovir is an experimental drug made by the US company Chimerix in Durham, North Carolina.